Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 4 results out of 4

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Castration-Resistant Prostate Cancer (CRPC)

Data Insights

Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to...

Data Insights

Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Sections

Sections

Sections

Sections

Sections

Company Profiles

Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Vobramitamab duocarmazine by MacroGenics for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

Vobramitamab duocarmazine by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval